BIO-Europe Spring, organised by EBD Group and the first major international biotech meeting of the year, took place in Vienna, Austria last week, attracting almost 3,000 attendees from the biotech, pharma and life science finance sectors. About 150 companies from more than 50 countries were there, almost 15,000 one-to-one meetings were held and about 3,000 licensing opportunities presented.
BIO-Europe Spring is a truly comprehensive event, commencing with a number of ‘pre-Event Programs’ on the weekend prior to the event proper – these included courses on topics such as negotiating deals, product valuation and deal structuring. The main event itself commenced on Sunday, March 24 with the official Welcome Reception and the opening of the BIO-Europe Spring exhibition. Networking events commenced the following day, Monday, March 25, the first consisting of a presentation and panel discussion on ‘The perfect pitch: do you have what it takes to win over investors?’, which included a competition in which members of the audience were each given 30 seconds to make an elevator pitch to the prestigious panel of expert investors: the best were then given the opportunity to give a more in-depth, two-minute presentation to the judges and the overall first- and second-placed winners received a 30-minute meeting with the investor of their choice. An excellent opportunity for start-ups to promote themselves and perhaps obtain investment funding!
Similar networking and one-to-one meetings took place throughout the day, and the first plenary discussion,’Time to turn the ship: Exploring underserved therapeutic areas’, was held. Other plenary presentations included ‘Who wins the seat when investing in European biotech companies’, ‘Evolving biopharma landscape in Asia-Pacific’ and ‘Product development and market access: the transformational changes within China’. The first of BIO-Europe Spring’s Power up parneringONE sessions also took place on Monday and explored best practices for collaborating with colleagues and increasing response and acceptance rates when looking to establish new partnerships.
The next day: Tuesday, March 26
Tuesday, March 26 and the programme also commenced with one-on-one meetings. The day also featured a presentation on new partnership and investment models: this was followed by a series of company presentations that included ‘Startup Spotlight Company Presentations’ by a dozen new biotech/pharma technology companies. The plenary session presentation on Tuesday was ‘A day in the life of experienced dealmakers’: other presentations that followed included a case study, ‘Following the client’s demand: Expanding from Europe to the US’, and ‘Pushing the boundaries: Digital technologies transforming the biopharma value chain’. More Power up partneringONE presentations followed, as well as another round of one-to-one meetings.
The final day: Wednesday, March 27
On Wednesday, March 27, presentations on ‘Gut instincts: Latest partnerships and collaboration models in microbiome’ and ‘How does Europe set the price for a new drug?’ were given, as were more company presentations. There was also a further Power up partneringONE session and a major pre-conference workshop, ‘Navigating the regulatory landscape for microbiome therapeutics’, was held, the Microbiome Therapeutics Conference itself occurring on Thursday, March 28 and Friday, March 29. The final presentations at BIO-Europe Spring this year were ‘The 5 most important upcoming trends in European biotech’ and ‘What’s lying ahead for European biotech in 2019 and beyond’.
It’s Paris next year!
So don’t miss out next year – BIO-Europe Spring will take place in Paris, France from Monday, March 23 to Wednesday, March 25, 2020: for further information visit www.ebdgroup.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- COMPANY UPDATE: Metrion Biosciences and the potential for ion channel drug discovery